Millions of people in low and middle income countries are set to get access to a game-changing HIV prevention drug within weeks, after US health authorities green lit a cheap form of the product.
Earlier this week the US Food and Drug Administration granted tentative approval to a generic form of the drug lenacapavir , made by Indian manufacturer Dr Reddy’s Laboratories.
Under an agreement hammered out between drug manufacturers and philanthropic donors in 2025 120 low and middle income countries across Africa, Asia, the Middle East and the Caribbean, will get access to the generic drug , at just $40 per patient per year – compared to the US list price of $28,000.
Lenacapavir, a long-acting injection administered twice a year, was hailed as the scientific breakthrough of 2024 and a potential turning point in the fight against HIV.…